External Committees
ICER has an advisory board which provides strategic guidance to ICER’s leadership team. Each of ICER’s core programs also has a non-governing advisory board. Composed of leading representatives from provider groups, public and private payers, patient groups, and purchasers, the program advisory boards help ensure that all reviews are actionable for a variety of stakeholders.
Advisory Board
- Harold Carter, PharmD, Senior Director, Clinical Solutions, Express Scripts
- Robert W. Dubois, MD, PhD, Chief Science Officer, National Pharmaceutical Council
- Patrick Gleason, PharmD, Assistant Vice President, Health Outcomes, Prime Therapeutics
- Ross Hoffman, MD, Chief Medical Officer, Envolve Pharmacy Solutions
- Kjel A. Johnson, PharmD, Vice President, Specialty Strategy and Client Solutions, CVS Health
- Myoung Kim, PhD, MA, MIBS, MBA, Vice President and Head, US Heath Economics and Outcomes Research and Medical Access, Novartis
- Andreas Kuznik, Senior Director, Health Economics and Outcomes Research, Regeneron Pharmaceuticals
- Chris Leibman, PharmD, Senior Vice President, Value and Access, Biogen
- Bryan Loy, MD, Market Medical Officer, Humana
- Mark McClellan, MD, PhD, founding Director of the Duke-Margolis Center for Health Policy, Duke University
- Ron Preblick, PharmD, MPH, Sr. Director, Global Business Partner, Rare Blood Disorders, Sanofi
- Matthew Rousculp, PhD, MPH, Head, US Value, Evidence and Outcomes, GlaxoSmithKline
- Michael Sherman, MD, MBA, MS, Senior Vice President and Chief Medical Officer, Harvard Pilgrim Health Care
- David R. Strutton, PhD, MPH, Vice President, Global Pharmaceuticals and Policy Evidence Research, Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc.
- Sean D. Sullivan, PhD, MSc, Professor and Dean, University of Washington School of Pharmacy
- Marcus Thygeson, MD, Chief Health Officer, Bind Benefits
- Sepideh Varon, PhD, MPH, Vice President, Health Economics and Outcomes Research, AbbVie
- John Watkins, PharmD, MPH, BCPS, Pharmacy Manager, Formulary Development, Premera Blue Cross
- David Weinstock, MD, Professor of Medicine and Pediatrics, Harvard Medical School and Dana-Farber Cancer Institute
- Jeff White, PharmD, MS, Staff Vice President, Clinical Pharmacy Services, IngenioRx
- Gergana Zlateva, PhD, MPA, Inflammation & Immunology Business Unit Lead, Patient & Health Impact, Pfizer